In the second episode of our mini-series "Conversations about Hypertrophic Cardiomyopathy", Dr Ankur Kalra sat down with Dr Ahmad Masri to have a deep-dive into the management paradigms of hypertrophic cardiomyopathy (HCM), considering the evolution of medical therapy in recent years. Dr Ahmad Masri is a Cardiologist and the Director of OHSU Hypertrophic Cardiomyopathy Center.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.
Dr Kalra invites Dr Masri to guide us through his decision-making process in evaluating medical and surgical options in patients with obstructive hypertrophic cardiomyopathy. Dr Masri delves into first and second-line treatment strategies while exploring the significance of FDA-approved cardiac myosin inhibitors in the management of hypertrophic cardiomyopathy. Dr Kalra asks Dr Masri about the practical office-based clinical course for patients deemed suitable candidates to receive mavacamten. Dr Masri provides a clear and practical outline of what it entails to opt for this second-line medical therapy including the REMS programme required for therapy (www.camzyosrems.com). Dr Masri highlights the importance of looking at HCM patients holistically to find the treatment which best fits their circumstances and preferences in choosing surgical and medical therapy options.
What are the available management options for patients with HCM? How does Dr Masri approach shared decision-making in the management of HCM? What are some of the practical considerations regarding the cardiac myosin inhibitor, mavacamten?
This content is intended for US-based physicians.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb.
Dr Owens is Medical Director of the Center for Inherited Cardiac Disease and Associate Professor of Medicine at the Hospital of the University of Pennsylvania.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.
This content is intended for US-based physicians.
In this week's latest podcast episode, host, Ankur Kalra, MD, meets guest Prof Madhav Swaminathan (Duke University Health System, NC, US) to discuss how he has orchestrated a major humanitarian effort, in association with Duke University Health and The American Society of Echocardiography, to supply ventilation equipment and PPE to hospitals and NGOs during the current COVID-19 crisis in New Delhi, India.
Hear them discuss the challenges and learnings associated with the supply chain, inventory, logistics and cost to deliver this humanitarian effort; which most recently resulted in $140,000 of life-changing equipment being delivered to four key hospitals in New Delhi. A most inspirational episode.
In this candid and spiritual conversation Amit and Ankur take a journey through former episodes of Parallax and Ankur’s writings to explore what it takes to strive for a deeper knowledge of ourselves; or, as Ankur puts it, dharma, the inherent order of reality.
Parallax’s guest this week is Dr Eric David Adler, Medical director of heart transplant and mechanical circulatory support at UC San Diego Health.
How did Dr Gragossian receive her diagnosis? How does she feel about her new reality? What drives her? What is her message to our listeners?
Just after 9/11, Heval, the 18-year-old Syrian Kurdish refugee found a job as a dishwasher. At this point, he was the sole provider of his family. The pressure that comes from being poor did not leave him for many years. Today, he is firm believer in giving back to underserved communities by spreading awareness within the medical community. As he says, well-meaning people of privilege are sometimes afraid to act. What we need is more people to bridge the gap and find ways to help each other.
What drives Dr Nishtha Sodhi? What were the formative moments of Dr Sodhi’s career? What are the new frontiers of cardiology?
In this week’s episode Ankur’s guest is Dr Mandeep R Mehra, Medical Director of Brigham Heart and Vascular Center and Professor of Medicine at Harvard Medical School.
Which COVID19 patients require risk stratification with a stress test? What are the take-home messages for physicians taking care of patients diagnosed with COVID19? What were the key trials of 2020? What can we learn from the negative results of the STRENGHT study? How have studies like STOP-AF influenced clinical practice?
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.